Concord News Now

Amyotrophic Lateral Sclerosis (ALS) Market

DelveInsight’s “Amyotrophic Lateral Sclerosis- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the ALS, historical and forecasted epidemiology as well as the ALS market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The ALS market report provides current treatment practices, emerging drugs, ALS market share of the individual therapies, and current and forecasted ALS market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current ALS treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key Highlights from the Amyotrophic Lateral Sclerosis (ALS)  Market Report

• ALS is the most common form of motor neuron disease in adults. Most people develop ALS between the ages of 40 and 70, with an average age of 55 at the time of diagnosis.
• Studies suggest that military veterans are about 1.5–2 times more likely to develop ALS. Although this is unclear, possible risk factors for veterans include exposure to lead, pesticides, and other environmental toxins. ALS is recognized as a service-connected disease by the US Department of Veterans Affairs

Learn more about the key trends and developments driving the market growth @ Amyotrophic Lateral Sclerosis Market Landscape

Amyotrophic Lateral Sclerosis (ALS)  Overview

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body. 

There is no cure and no proven treatment for ALS. However, available treatments can help control symptoms, prevent unnecessary complications, and make the patient’s life easier. The disease progresses over 3–5 years, making voluntary movements of arms and legs impossible. In time, the patient will need help with personal care, eating, and mobility. Movement of the diaphragm for breathing is also impaired, and the patient may need a ventilator for breathing. Most people with ALS die from respiratory failure. For most people with ALS, the main treatment may involve the management of symptoms. Supportive care is best provided by multidisciplinary teams of healthcare professionals such as physicians, pharmacists, therapists—physical, occupational, and speech—nutritionists, social workers, respiratory therapists, clinical psychologists, and home care and hospice nurses.

Amyotrophic Lateral Sclerosis (ALS) Epidemiological Insights :

• A study conducted by Wagner et al. (2018) titled “Estimation of the Prevalence of Amyotrophic Lateral Sclerosis in the United States Using National Administrative Healthcare Data from 2002 to 2004 and Capture-Recapture Methodology”, used three sources: Medicare, Medicaid, and Veterans Administration data to estimate the prevalence of ALS in the US for 2002–2004 and applied the capture-recapture methodology to estimate the degree of under-ascertainment. In this study, the annual prevalence was estimated to be approximately 3.7/per 100,000 population in 2002, 4.4/per 100,000 population in 2003, and 4.8/per 100,000 population in 2004.  The study also examined sex and age-related epidemiological data, which suggested that among 9,705 cases considered, 59.7% were males, 46.7% were 65 years. Overall, for the years 2002 through 2004, the number of ALS cases observed across sources increased linearly, from 8,005 in 2002 to 9,705 in 2003 to 10,732 in 2004.
• Camacho et al. (2018) in the study titled “Report by the Spanish Foundation for the Brain on the social impact of amyotrophic lateral sclerosis and other neuromuscular disorders” suggested that ALS was estimated to affect 3 new patients per day in Spain, with the ALS cases being over 3000 in Spain. The study also highlighted that ALS’s prevalence (which is dependent on survival and is therefore affected by the development of new treatments) is low due to high mortality rates and ranges between 2–5 cases/100 000 population
• Rosenbohm et al. (2017) In the study titled ” Epidemiology of amyotrophic lateral sclerosis in Southern Germany”, found that the site of onset of ALS was more frequently bulbar (34.1%) than lumbosacral (30.7%), cervical (27.0%), or thoracic (3.1%). In terms of gender-specific data, out of 699 cases, 379 were males, and 284 were females. The study suggested that the males-to-females ratio can be as high as 2.6∶1. Additionally, it was estimated that the prevalence of ALS was about 8/100,000 person-years, meaning that about 6,400 patients with ALS were living in Germany, and this prevalence is expected rise to about 9.2–9.8/100,000 person-years in Germany in 2050. The prevalent population of ALS in the seven major markets was found to be  71,628 in 2020. The diagnosed prevalent cases of ALS, in the United States, were found to be  18,824 in 2020.

Amyotrophic Lateral Sclerosis (ALS) Epidemiology Segmentation

The Amyotrophic Lateral Sclerosis epidemiological analysis for the study period 2019-32 in the 7MM segmented into

• Amyotrophic Lateral Sclerosis prevalent population
• Amyotrophic Lateral Sclerosis gender-specific cases
• Amyotrophic Lateral Sclerosis age-specific distribution 
• Amyotrophic Lateral Sclerosis site of onset 
• Amyotrophic Lateral Sclerosis type-specific cases 

Download the Amyotrophic Lateral Sclerosis market report to understand which factors are influencing epidemiology trends @Amyotrophic Lateral Sclerosis Market Landscape

Amyotrophic Lateral Sclerosis (ALS)  Market Outlook

Amyotrophic lateral sclerosis (ALS) is a group of rare neurological diseases mainly involving the nerve cells (neurons) responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time.

Currently, there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. The treatment landscape of ALS includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpool therapy and others. Medications are also prescribed to help manage symptoms of ALS, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar effect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs also are available to help individuals with pain, depression, sleep disturbances, and constipation.

To know more about Amyotrophic lateral sclerosis please visit @ Amyotrophic Lateral Sclerosis market 

Amyotrophic Lateral Sclerosis (ALS)  Market Drivers 

• Availability of Genuine Epidemiological Data
• Robust Pipeline Activity
• Increasing Awareness  Programs

Amyotrophic Lateral Sclerosis (ALS)  Market Barriers 

• High Medical Cost
• Lack of Proper Diagnosis
• High Mortality Rate
• Dominance of a few drugs for the treatment 

Amyotrophic Lateral Sclerosis (ALS)  Key Companies

•  Mitsubishi Tanabe Pharma Corporation
•  Sanofi/Covis
•  Aquestive Therapeutics
•  Avanir Pharmaceuticals 
• and many more 

Amyotrophic Lateral Sclerosis Key Therapy areas 

• NurOwn 
• Ibudilast
• Tofersen
• Verdiperstat 
• and many more 

Discover more about therapies set to grab major market share @ Amyotrophic Lateral Sclerosis Market therapeutics outlook

Table of Contents

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/